Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Myocardial Infarction.

As weight-loss drugs have exploded in popularity this past year, part of the craze has been members of the public wondering which celebrities are on Ozempic.

Nordic firms have outperformed those from the rest of Europe over the past decade. In all four countries, listed ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

A big rally in defense stocks, deal-fueled gains in banks and a surge in Siemens Energy AG shares were among the main ...

Eli Lilly and Novo Nordisk are likely to introduce its popular injectable drugs semaglutide and tirzepatide in India in 2025.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

Following billionaire investors isn't as difficult as you might imagine thanks to quarterly reporting required by the ...

This time last year, people were still bickering about whether Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound represented a shortcut to losing weight or a medical breakthrough. But with reams of ...